Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06304857 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL

Study acronym: PROTECTAA
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study Identification, Study Status, IPDSharingv5
  2. Site details revised at 1 of 3 sitesv4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 1, 2024 to Apr 15, 2024
    • Site details revised at 3 of 3 sites
    v3
  4. Eligibility criteria expanded, about 101 wordsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of cancer therapeutics-related cardiac dysfunction in patients with breast cancer receiving anthracycline treatment.
Trial Details
NCT Number NCT06304857
Lead Sponsor 4th Military Clinical Hospital with Polyclinic, Poland
Conditions
(from sponsor)		 Breast Cancer, Heart Failure
Related terms Breast Neoplasms, Heart Failure
Enrollment 188 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov